Key result
Early cardiac troponin I > 5.6 ng/mL was associated with a higher risk of long-term death or reinfarction after CABG in patients with ACS (HR 2.58; 95% CI 1.05-6.36; p=0.039).
Why the study?
Does early cardiac troponin I level predict long-term death or reinfarction in patients with acute coronary syndrome undergoing CABG?
Cohort (n=160)
No
Does early cardiac troponin I level predict long-term death or reinfarction in patients with acute coronary syndrome undergoing CABG?
Hazard Ratio: 2.58 (95% CI 1.05–6.36)
p-value: p=0.039
Early measurement of cardiac troponin I (specifically >5.6 ng/mL) upon admission independently predicts long-term death or reinfarction in patients with ACS undergoing CABG.
BACKGROUND: High values of both preoperative and postoperative cardiac troponin I (cTnI) contribute to higher rates of short-term cardiac events following coronary artery bypass graft (CABG) surgery in patients with acute coronary syndrome (ACS). The prognostic value of very early cTnI in this context is unclear. HYPOTHESIS: Measurement of cTnI very early after admission to the emergency room can be used as a prognosticator for long-term outcomes after CABG. METHODS: We conducted a cohort study on 160 consecutive patients with ACS undergoing CABG at The John H. Stroger Jr. Hospital of Cook County (Chicago, IL) representing a total follow-up of 290.42 person-years. Adverse outcomes were defined as death or reinfarction. We used robust multivariate survival analyses to determine whether early cTnI measurement can independently predict the adverse outcomes in the study subjects. RESULTS: In univariate and stepwise multivariate Cox proportional hazards modeling we found that unit rise in early cTnI is associated with a 3% (95% confidence interval [CI]: 2%- 5%, p < 0.001) faster progression to long-term adverse events after CABG even after adjusting for the type of ACS. Prognostically, the most informative cut off value for cTnI was 5.6 ng/mL. Above this value, CABG patients progressed 2.58 times faster to adverse outcomes (95% CI: 1.05-6.36, p = 0.039). This effect remained after adjustment for other significant confounders namely, poor compliance to medications, female sex, Medicaid insurance, and electrocardiographic ischemia. CONCLUSION: Early cTnI measurement after admission can predict adverse outcomes after CABG. This association extends to long-term adverse events after CABG.
No takes yet. Share an insight, caveat, or question.
Amin et al. (2009) conducted a cohort in Acute Coronary Syndromes undergoing CABG (n=160). Early cardiac troponin I (cTnI) > 5.6 ng/mL vs. Early cTnI ≤ 5.6 ng/mL was evaluated on Death or reinfarction (HR 2.58, 95% CI 1.05-6.36, p=0.039). Early cardiac troponin I > 5.6 ng/mL was associated with a higher risk of long-term death or reinfarction after CABG in patients with ACS (HR 2.58; 95% CI 1.05-6.36; p=0.039).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: